Show simple item record

dc.contributor.authorVargas, M.
dc.contributor.authorVillarraga, E.
dc.contributor.authorVargas, Jba
dc.date.accessioned2019-06-12T16:06:05Z
dc.date.available2019-06-12T16:06:05Z
dc.date.issued2014
dc.identifier.citationVargas M, Villarraga E, Vargas Jba (2014) Bioequivalence Study of Two 50 mg Desvenlafaxine Extended Release Formulations: A Randomized, Single-Dose, Open-Label, Two Periods, Crossover Study. J Bioequiv Availab 6: 115-118. doi: 10.4172/jbb.10000189
dc.identifier.issn0975-0851
dc.identifier.otherhttps://www.omicsonline.org/open-access/bioequivalence-study-of-two-mg-desvenlafaxine-extended-release-formulations-a-randomized-singledose-openlabel-two-periods-crossover-study-jbb.1000189.php?aid=30141
dc.identifier.urihttp://hdl.handle.net/10818/35845
dc.description4 páginases_CO
dc.description.abstractThis is a pharmacokinetic study of two formulations containing Desvenlafaxine succinate 50 mg extended release. Its objective was to compare the bioavailability between the Test product (Desvenlafaxine ER produced by Tecnoquímicas S.A., Colombia laboratory) and the Reference product (Pristiq XR® produced by Wyeth laboratory) and to be able to determine the Bioequivalence between the both of them. For this, an open label, two periods, two previously randomized sequences, crossover, single postprandial 100 mg dose study with an 8 days washout period between each period in 24 healthy volunteers was performed, including the collection of 13 plasma samples within 0 and 48 hours from all volunteers who participated in the clinical phase. The analytical method used was High Performance Liquid Chromatography (HPLC) with UV detector. The obtained mean peak concentration (Cmax) for the Test and Reference products were 215.8 ng/mL and 196.9 ng/mL and for the area under the curve up to 48 hours (AUC0-t) 3849,6 ng.h/mL and 3605,4 ng.h/mL respectively. The 90% confidence interval for the Cmax parameter is within the range of 103,58-113,63 and for the AUC0-t parameter, the 90% confidence interval is within 97,96-111,39. Based on the FDA, EMA and WHO bioequivalence investigation guidelines, the CI is within the allowed ranges for bioequivalence and interchangeability declaration of the Tecnoquímicas S.A. product with the Reference product.es_CO
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherJournal of J Bioequivalence & Bioavailabilityes_CO
dc.relation.ispartofseriesBioequiv Availab 6(4) 115-118 (2014)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabanaes_CO
dc.sourceIntellectum Repositorio Universidad de La Sabanaes_CO
dc.subjectBioequivalencees_CO
dc.subjectDesvenlafaxinees_CO
dc.subjectAntidepressantes_CO
dc.subjectPharmacokineticses_CO
dc.titleBioequivalence Study of Two 50 mg Desvenlafaxine Extended Release Formulations: A Randomized, Single-Dose, Open-Label, Two Periods, Crossover Studyes_CO
dc.title.alternativeBioequivalence Study of Two 50 mg Desvenlafaxine Extended Release Formulations A Randomized, Single-Dose, Open-Label, Two Periods, Crossover Studyes_CO
dc.typearticlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcept where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International